3月18日A股投資避雷針︱英集芯:終止籌劃重大資產重組事項 股票復牌;中巨芯:股東遠致富海擬減持不超3%股份
傳藝科技實控人鄒偉民及其一致行動人擬減持合計不超3%股份;申科股份股東易城易購擬減持不超3%股份;本川智能控股股東董曉俊擬減持不超3%股份;中巨芯股東遠致富海擬減持不超3%股份;莎普愛思股東上海景興及陳德康擬合計減持不超6%股份;鈞達股份2024年度淨虧損5.91億元;盟科藥業2024年淨虧損4.4億元;英集芯終止籌劃重大資產重組事項 股票復牌;*ST傲農在金融機構新增逾期的債務本息合計約9876.19萬元

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.